Back ground Patients with dystrophic epidermolysis bullosa (DEB) experience various degrees of widespread recurrent skin blistering and erosions that characteristically heal with exuberant scarring and milia formation. DEB may lead to the development of skin cancers. Advances in understanding the pathogenesis of EB in the last decade have led to the development of several therapeutic strategies. Objective To investigate the effectiveness of the combined use of granulocyte-colony-stimulating factor (GCSF) and mycophenolate mofetil (MMF) in the treatment of DEB and to compare our results with those of the previous studies that used either GCSF alone or MMF alone. Patients and methods Fifty-one patients with DEB were enrolled into this study. They were clinically assessed for total body blisters and erosions (both count and size) and scored using the Birmingham scoring system. Results There were significant improvements (P<0.001) with the use of combined treatment which was superior to each treatment alone. Conclusion Subcutaneous GCSF combined with MMF was shown to be superior to the use of either MMF or GCSF alone, in decreasing the rate of blister formation and in wound healing in patients with DEB.

Mycosis fungoides (MF) is a great imitator. It can resemble more than 50 different clinical disorders. Porokeratosis is the rarest of the disorders and has been reported only in three cases. Herein, we present three cases of porokeratosis occurring in MF patients. The first case proved to be MF lesions upon histopathological examination, whereas the second case showed a classic porokeratosis occurring in association with MF in the same lesion. Finally, the third case was presented with classic porokeratosis that developed in a longstanding MF case undergoing treatment with Methotrexate and PUVA.

Psoriasis is a chronic inflammatory disorder of the skin, with genetic factors reportedly involved in the disease pathogenesis. Numerous studies reported psoriasis candidate genes. However, these tend to involve mostly in the European and Asian populations. Here, we report the first genome‐wide association study (GWAS) in an Egyptian population, identifying susceptibility variants for psoriasis using a two‐stage case‐control design. In the first discovery stage, we carried out a genome‐wide association analysis using the Infinium® Global Screening Array‐24 v1.0, on 253 cases and 449 control samples of Egyptian descent. In the second replication stage, 26 single‐nucleotide polymorphisms (SNPs) were selected for replication in additional 321 cases and 253 controls. In concordance with the findings from previous studies on other populations, we found a genome‐wide significant association between the MHC locus and the disease at rs12199223 (Pcomb = 6.57 × 10−18) and rs1265181 (Pcomb = 1.03 × 10−10). Additionally, we identified a novel significant association with the disease at locus, 4q32.1 (rs12650590, Pcomb = 4.49 × 10−08) in the vicinity of gene GUCY1A3, and multiple suggestive associations, for example rs10832027 (Pcomb = 7.28 × 10−06) and rs3770019 (Pcomb = 1.02 × 10−05). This proposes the existence of important interethnic genetic differences in psoriasis susceptibility. Further studies are necessary to elucidate the downstream pathways of the new candidate loci.